High Vista Strategies LLC Biomarin Pharmaceutical Inc Transaction History

High Vista Strategies LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$86.68 - $100.3 $148,049 - $171,312	-1,708 Reduced 17.61%	7,993 $692,000
Q4 2022 Feb 14, 2023	SELL	$80.93 - $108.63 $9,711 - $13,035	-120 Reduced 1.22%	9,701 $1 Million
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $100,646 - $118,751	1,225 Added 14.25%	9,821 $833,000
Q2 2022 Aug 15, 2022	BUY	$71.48 - $86.85 $214,654 - $260,810	3,003 Added 53.69%	8,596 $712,000
Q1 2022 May 16, 2022	BUY	$74.28 - $92.69 $415,448 - $518,415	5,593 New	5,593 $431,000
Q3 2020 Nov 16, 2020	SELL	$71.87 - $131.03 $243,208 - $443,405	-3,384 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$79.55 - $124.22 $269,197 - $420,360	3,384 New	3,384 $417,000

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of High Vista Strategies LLC, based on Form 13F filings with the SEC.

Stay updated on High Vista Strategies LLC with notifications on news.